Key facts
- Amaros’s last known valuation is $4.7M (Jul 2019).
- It has raised $2.0M across 1 recorded rounds; the latest was Seed Round ($1.3M) in Mar 2025.
- Notable investors include Wilson Sonsini Goodrich & Rosati, Hero House (Armenia), SmartGateVC, Yoshimei.
- Amaros has filed 1 Form D with the SEC, most recently Apr 2025 ($1.3M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Amaros
Funding rounds
1 roundsAbout Amaros
Developer of an AI-powered platform designed to support clinical and post-market decision-making in ophthalmology. The company's platform collects, structures, and analyzes large datasets to accelerate clinical trial enrollment, generate real-world evidence, and identify market opportunities for life sciences companies, enabling clients to get access to faster and more informed therapeutic development methods.
- Sector
- Healthcare
- HQ
- Atherton, CA, United States
- Founded
- 2019
- Employees
- 14
- Website
- amaros.ai/
- Ownership
- Privately Held (backing)
Amaros doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amaros shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amaros in its N-PORT filings yet. We sweep new filings monthly.